Introduction
Dermatology ( Deutsche Dermatologische Gesellschaft, DDG ) present the options available for systemic drug therapy in patients with various types of leg ulcers and discuss their use in the context of their approval status.
Drugs for the treatment of leg ulcers
In Germany, numerous systemic drugs are approved for the indication "leg ulcer" without further specifi cation. Many of these substances -including bencyclane fumarate, sodium pangamate, propyphenazone, cytochrome C, cyclandelate, or troxerutin -are herbal or homeopathic agents. These drugs are not further discussed in this review; neither are antibiotics and agents exclusively approved for specifi c situations. One such example is the coagulation factor XIII, which is approved for patients with leg ulcers following extensive surgery. Table 1 Disorders and factors that may play a role in the development of chronic leg ulcers.
Vascular disease, e. g. CVI, PAD (Auto-)immune disorders, e. g. vasculitis, pyoderma gangrenosum Neoplasms, e. g. basal cell carcinoma, squamous cell carcinoma Metabolic disorders, e. g. diabetes, calciphylaxis Infectious diseases, e. g. mycobacteriosis, leishmaniasis Neurologic disorders, e. g. polyneuropathy, spina bifida Exogenous factors, e. g. thermal effects, artifacts Drugs, e. g. hydroxyurea, coumarine derivatives Hematologic disorders, e. g. sickle cell disease, essential thrombocythemia Genetic diseases, e. g. Klinefelter syndrome, progeria Table 2 Selection of drugs that have been suggested to cause leg ulcers (modified after [ 3 ] 
Venous leg ulcer
The term "venous leg ulcer" encompasses all skin defects resulting from venous hypertension ( Figure 1 ). Venous hypertension may be due to structural (for example, varicose veins) and functional causes (arthrogenic congestion syndrome). Based on current guidelines, apart from medical history and clinical examination, the basic diagnostic workup includes arterial and venous studies using Doppler or -better -duplex ultrasound. Additional diagnostic tests are only required to rule out differential diagnoses. Whenever possible, treatment should be geared towards fi xing the underlying cause and at least include adequate compression therapy [ 5 ] . If possible, existing structural changes should be eradicated by ablation or surgery [ 6 ] .
Even with optimal management, however, approximately 30 % of patients do not respond to treatment and the ulceration persists. In such cases, supplementary systemic treatment may be considered. In recent years, there have been numerous studies investigating drugs and dietary supplements that are supposed to have antiinfl ammatory effects and/or improve circulation. These agents are listed below; the numbers in brackets refer to the relevant studies or meta-analyses:
The term "venous leg ulcer" encompasses all skin defects resulting from venous hypertension.
Even with optimal management, however, approximately 30 % of patients do not respond to treatment and the ulceration persists. In such cases, supplementary systemic treatment may be considered. Figure 1 Typical venous leg ulcer on the medial aspect of the distal lower leg, showing clinical signs of chronic venous insufficiency such as hyperpigmentation (purpura jaune d'ocre), corona phlebectatctica paraplantaris, stasis dermatitis and edema.
-Acetylsalicylic acid [ 7 ] , -Doxycycline [ 8 ] , -Low-molecular-weight heparins, e. g. nadroparin [ 9 ] , -Pentoxifylline [ 10 ] , -Statins, e. g. simvastatin [ 11 ] , -Sulodexide [ 12 ] , -Phytotherapeutic agents such as fl avonoids, pycnogenol, and mesoglycan [13] [14] [15] , -Dietary supplements such as zinc and folic acid [ 16, 17 ] .
The majority of studies showed positive results for the various therapeutic approaches with respect to reduction in wound size, duration of wound healing as well as wound healing and recurrence rates. One randomized clinical trial (RCT) of 66 patients with chronic venous leg ulcer found signifi cant improvement in wound healing by systemic administration of simvastatin (40 mg/d). In the patient group with ulcers ≤ 5 cm, 100 % of lesions resolved in the simvastatin arm compared to 50 % in the control arm. In patients with an ulcer size > 5 cm, healing rates were 67 % in the simvastatin arm and 0 % in the control arm after an average of nine weeks [ 11 ] .
However, frequent points of criticism expressed in the meta-analyses and Cochrane reviews include the very small sample sizes, methodological approaches, and a marked bias in reporting. Thus, no conclusive recommendations can be given based on study data currently available. All systemic agents used in the treatment of venous leg ulcers are off-label.
In Germany, the following substances with evidence-based effi cacy are available for symptomatic treatment of CVI and edema reduction: calcium dobesilate [ 18 ] , oxerutin [ 6 ] , standardized horse chestnut extract [ 14 ] , and standardized red vine leaf extract AS 195 [ 14 ] .
However, their use in the treatment of venous leg ulcers has not been explicitly studied. The 2013 Dutch guidelines on the management of leg ulcers recommend the use of acetylsalicylic acid or pentoxifylline for recalcitrant ulcerations. A Cochrane review concludes that pentoxyfylline may promote healing of venous ulcers, whereas oral administration of zinc is considered ineffective [ 17 ] .
Arterial leg ulcers
PAD is a common and important cause and/or comorbidity in patients with leg ulcers. In this context, several aspects should be considered in the diagnostic workup:
-Patients with (venous) leg ulcers may have well-compensated PAD with an absolute ankle pressure of > 70-80 mm Hg without any signifi cance as regards wound healing. -While the primary cause of mixed leg ulcers is usually CVI, PAD with an absolute ankle pressure < 70-80 mm Hg does contribute to delayed wound healing. -PAD with an absolute ankle pressure < 50-60 mm Hg is the primary cause of arterial leg ulcers.
Irrespective of the presence of leg ulcers, secondary prevention of atherosclerosis is indicated in all patients with PAD to improve life expectancy and decrease the likelihood of amputation. This includes physical activity, smoking cessation, weight loss, optimal management of diabetes and arterial hypertension, use of antiplatelet drugs, and decrease of LDL cholesterol using statins. These therapeutic measures for secondary prevention may potentially have an impact on ulcer healing, too. Walking exercises are also known to promote wound healing. Revascularization procedures are generally indicated in patients with arterial leg ulcers to All systemic agents used in the treatment of venous leg ulcers are off-label.
Systemic administration of acetylsalicylic acid or pentoxifylline may be considered in recalcitrant disease.
PAD is a common and important cause and/or comorbidity in patients with leg ulcers.
Irrespective of the presence of leg ulcers, secondary prevention of atherosclerosis is indicated in all patients with PAD.
Revascularization procedures are generally indicated in patients with arterial leg ulcers.
increase arterial perfusion. At least for incisional wounds, it has been shown that abstinence from smoking decreases the risk of wound infections [ 19 ] . Prostaglandins and prostacyclins are available for pharmacological treatment of critical limb ischemia associated with mixed ( Figure 2 ) and arterial leg ulcers, which are usually very painful. The current Cochrane meta-analysis on the effi cacy of prostanoids in patients with chronic critical ischemia showed positive effects with respect to ulcer healing, pain reduction, and reduction in amputation rates compared to placebo or other active control therapies [ 20 ] . By contrast, the RCT ESPECIAL with more than 800 patients with chronic critical ischemia failed to provide any evidence of the benefi cial effects of alprostadil compared to placebo [ 21 ] . However, this study has signifi cant methodological limitations and thus stands in contrast to the clinical benefi ts observed in some patients.
Livedoid vasculopathy
Livedoid vasculopathy (LV) is a chronic recurrent disorder of cutaneous microcirculation resulting in painful ulcerative lesions of the lower extremities, in particular of the malleolar region [ 22 ] (Figure 3 ). While the cause of the disease is not yet fully understood, it has been established that procoagulant mechanisms are involved, which lead to fi brin deposition and subsequently intraluminal thrombosis of small cutaneous vessels [ 23 ] . Clinical correlate of the resulting malperfusion is a triad of symptoms consisting of livedo racemosa, painful ulcerations, and atrophie blanche. The irregularly formed markings of livedo racemosa show that neighboring vessels partially compensate for the occlusion-related malperfusion of cutaneous vessels. This physiological blood supply marks the basis for Prostaglandins and prostacyclins are available for pharmacological treatment of critical limb ischemia.
Livedoid vasculopathy is a chronic recurrent disorder of cutaneous microcirculation.
Triad of symptoms consisting of livedo racemosa, painful ulcerations, and atrophie blanche. the -occasionally -stellate ulcerations. Malperfusion leads to cutaneous ischemia causing the sharp pain referred to as angina cutis [ 24 ] . The diagnosis of LV is made on clinical grounds, the presence of painful ulcerations being a sine qua non. The diagnosis is confi rmed by a spindle biopsy showing thrombotic occlusion of skin capillaries. The biopsy must be taken from an acute erythematous/violaceous lesion. In the acute phase, LV can be distinguished from cutaneous polyarteritis nodosa by the absence of a primary perivascular infl ammatory infi ltrate, moreover, only superfi cial capillaries are affected. Based on what we know today, LV is a purely cutaneous disorder without any evidence of systemic involvement. At present, no substance is explicitly approved for the treatment of LV. The thrombotic character of the disease suggests the use of anticoagulants. Numerous case reports have demonstrated the effectiveness of low-molecular-weight heparins in particular [ 25 ] . In addition, the introduction of direct oral anticoagulants (DOACs) has brought about a new class of drugs. The largest RCT to date confi rmed the effi cacy of rivaroxaban in the treatment of LV [ 26 ] . To date, no approval study has been published. The optimal dosage and duration of treatment are currently still the topic of research [ 27 ] . In certain cases that do not respond to rigorous anticoagulation, treatment with immunoglobulins may be an alternative [ 28 ] . Although their mechanism of action has not yet been fully elucidated, one potential explanation may be the displacement of prothrombotic autoantibodies.
The diagnosis is confirmed by a spindle biopsy showing thrombotic occlusion of skin capillaries.
At present, no substance is explicitly approved for the treatment of LV.
Low-molecular-weight heparins and/ or rivaroxaban are the drugs of first choice. Calciphylaxis ( Figure 4 ) is a rare and potentially life-threatening disorder that presents with bizarrely shaped, exquisitely painful necrotic ulcers, primarily affecting the lower extremities, abdomen, or buttocks. Given the frequent occurrence of wound infections and also sepsis, mortality rates can be as high as 80 %. Histologically, calciphylaxis is characterized by a triad consisting of i) calcifi cation of the tunica media of venules, arterioles, and small cutaneous arteries, ii) thrombotic occlusion of these vessels, and iii) deep necrotic ulceration. The pathogenesis that facilitates these processes remains unknown [ 29 ] . There is a strong association with end-stage renal disease, need for dialysis, and kidney transplantation. Elevated serum calcium and phosphate levels are common. Apart from renal disease, risk factors include hyperparathyroidism, albumin defi ciency, obesity, and use of vitamin D3 analogs [ 29, 30 ] . Martorell's (hypertensive ischemic) ulcer, in particular, is an important differential diagnosis. Therapeutic options may include decreasing calcium and phosphate levels by increasing the frequency of dialysis. Calcium-containing phosphate binders should be avoided. Use of vitamin D3 analogs for the treatment of secondary hyperparathyroidism should be discontinued. It has been proposed that vitamin K antagonists may play a potential role in the accumulation of calcium salts in blood vessels [ 31 ] , and it has been shown that switching anticoagulation to low-molecular-weight heparins results in a clinical response [ 29 ] . The effect of vitamin K supplementation is currently being investigated in a clinical trial (ClinicalTrials.gov identifi er: NCT02278692).
Calciphylaxis is a rare and potentially life-threatening disorder.
There is a strong association with end-stage renal disease, need for dialysis, and kidney transplantation. Even though the exact mechanism of action is still unknown, several studies and case reports have shown that systemic administration of sodium thiosulfate, possibly in combination with cinacalcet, may be a promising approach [ 32 ] . The optimal dosage and duration of treatment are currently being investigated in the context of an RCT (ClinicalTrials.gov identifi er: NCT03150420). Bisphosphonates are another therapeutic alternative, albeit associated with more adverse effects in some cases [ 33 ] .
Necrobiosis lipoidica
Necrobiosis lipoidica ( Figure 5 ) is a rare granulomatous disorder of uncertain etiology associated with skin lesions that predominantly affect the extensor aspects of the lower legs [ 34 ] . Unusual locations, such as the scalp and the genital region, have also been described [ 35 ] . The extensive ulcerations within the infl ammatory plaques, which affect approximately 30 % of all patients, pose a therapeutic challenge [ 36 ] . In most cases, the skin lesions precede the ulcerations by several months or even years. While the condition is known to be associated with diabetes in at least 50 % of all patients, associations with other disorders of the metabolic syndrome [ 37 ] as well as thyroid disorders [ 36 ] have also been identifi ed in large patient populations. Given the small number of patients, there are currently no unequivocal recommendations with respect to treatment options. No agent has been approved for this indication. If associated with diabetes, rigorous diabetes management is key to therapeutic success [ 38 ] . With respect to systemic therapies, fumaric acid esters in particular are apparently becoming the treatment of choice. Although the data is still sketchy, published case series have shown a comparatively good response to treatment [ 39 ] . At present, therapeutic approaches using rheological agents, such as pentoxifylline and acetylsalicylic acid, appear to be less relevant; their use is corroborated primarily by older case reports. This is also true for cyclosporine, antimalarial drugs, or dapsone. By contrast, the use of biologics may be considered promising. However, given that their Systemic administration of sodium thiosulfate, possibly in combination with cinacalcet, is a promising therapeutic option.
Necrobiosis lipoidica is a rare granulomatous disorder of uncertain etiology.
While the condition is known to be associated with diabetes in at least 50 % of all patients, associations with other disorders of the metabolic syndrome as well as thyroid disorders have also been identified.
With respect to systemic therapies, fumaric acid esters in particular are apparently becoming the treatment of choice. use is off-label, it requires that the indication be chosen with care and that patients give informed consent. Nevertheless, the case reports published to date (primarily TNF α inhibitors [ 40 ] ) suggest an adequate response along with good tolerance, even though RCTs are still lacking. The evaluation of study data is complicated by low patient numbers, diffi cult-to-compare study designs, and lack of distinction between cases with and without ulcerations [ 41 ] . Overall, it must be concluded that the evidence currently available is insuffi cient to give defi nitive recommendations as regards the systemic treatment of necrobiosis lipoidica.
Leg ulcers associated with vasculitis
The term vasculitis comprises a group of disorders with relevance for various medical disciplines; they all have in common that they cause vascular infl ammation. A distinction is made between primary and secondary forms of vasculitis. Primary types of vasculitis are classifi ed according to the revised 2012 Chapel Hill classification [ 42 ] . Secondary vasculitides can be triggered by numerous drugs, including acetylsalicylic acid, allopurinol, nonsteroidal antiinfl ammatory drugs, or various antibiotics. Cutaneous involvement may be associated with leg ulcers ( Figure 6 ). Clinically, such ulcers are exquisitely painful and usually surrounded by a characteristic violaceous border.
Overall, it must be concluded that the evidence currently available is insufficient to give definitive recommendations as regards the systemic treatment of necrobiosis lipoidica.
The term vasculitis comprises a group of disorders with relevance for various medical disciplines that cause vascular inflammation. Figure 6 Leg ulcer in a patient with cutaneous leukocytoclastic angiitis.
Given that vasculitides constitute a very heterogeneous group of disorders, it is important to make a distinction between the various types when considering the approval status of certain drugs.
The corticosteroids prednisone, prednisolone, methylprednisolone, dexamethasone, and triamcinolone are approved for the treatment of vasculitis. Cyclophosphamide is approved for systemic vasculitis. Azathioprine is approved for polyarteritis nodosa. Rituximab is approved for patients with severe active granulomatosis with polyangiitis (Wegener's disease) and microscopic polyangiitis. Dapsone should only be used if corticosteroids alone are not suffi ciently effective. Its use is recommended for the treatment of temporal arteritis in particular.
Corticosteroids are generally the agents of fi rst choice in the majority of patients with leg ulcers associated with active vasculitis. In recent years, the anti-CD20 antibody rituximab has been used successfully, especially in recalcitrant cases. In clinical studies of up to 80 patients with various types of vasculitis, more than 90 % of patients achieved remission. However, 28 % experienced severe adverse effects -primarily infections -with a fatal outcome in 5 % of patients [ 43 ] . The only publications available regarding the treatment of vasculitis-related leg ulcers are individual case reports [ 44 ] .
Pyoderma gangrenosum
Pyoderma gangrenosum (Figure 7 ) is a rare neutrophilic disorder of uncertain origin associated with a genetic predisposition. It is a diagnosis of exclusion that can only be established based on typical clinical fi ndings and history, and after Several corticosteroids are approved for the treatment of vasculitis.
Cyclophosphamide is approved for systemic vasculitis. Azathioprine is approved for polyarteritis nodosa. Rituximab is approved for patients with severe active granulomatosis with polyangiitis (Wegener's disease) and microscopic polyangiitis.
Pyoderma gangrenosum is a rare neutrophilic disorder of uncertain origin associated with a genetic predisposition.
Figure 7
Exquisitely painful pyoderma gangrenosum; the lesion occurred after minimal trauma.
ruling out relevant differential diagnoses. The PARACELSUS score is useful in this regard [ 45 ] . Numerous studies point to a relevant association with comorbidities such as metabolic syndrome, rheumatoid arthritis, and chronic infl ammatory bowel disease. The potential association with (hematologic) neoplasms is of particular importance [ 46 ] . However, pyoderma gangrenosum may also be caused by drugs. According to a recent review of 52 cases, such agents primarily include cocaine, propylthiouracil, and sunitinib [ 47 ] . Only prednisone and prednisolone are approved for systemic treatment of pyoderma gangrenosum. To date, two RCTs on systemic treatment have been published. In one study of 30 patients with pyoderma gangrenosum, 13 patients received infl iximab; 17 patients were given placebo. After two weeks, 46 % of patients treated with infl iximab and 6 % of individuals given placebo showed clinical improvement. Patients were subsequently allowed to switch to the infl iximab arm, resulting in a response rate of 69 % (in 29 patients) [ 48 ] .
In another RCT, 121 patients with pyoderma gangrenosum were treated with either prednisolone (0.75 mg/kg/d) or cyclosporine (4 mg/kg/d). After six weeks of treatment as well as during follow-up, both study arms showed similar clinical improvement. Both drugs were therefore considered to be equally effective. The authors recommended that the choice of treatment be made on a case-by-case basis, taking into account the side effect profi le [ 49 ] . In clinical practice, the combination of prednisolone and cyclosporine frequently shows good results.
Treatment alternatives predominantly published in case reports and series include dapsone, azathioprine, mycophenolate mofetil, and intravenous immunoglobulins. Antibody therapies directed against proinfl ammatory cytokines such as interleukin (IL)-1 (anakinra, canakinumab), IL-12 and IL-23 (ustekinumab), and IL-17A (secukinumab) are novel, highly promising treatment options [ 50 ] .
Discussion

Approval status and off-label use
Many systemic drugs used in the treatment of patients with leg ulcers are not approved for this indication. Their use is therefore off-label. This refers to treatment with a fi nished medicinal product outside its approved indication(s). On principle, it is up to the physician to decide whether to use a drug for the treatment of a given disease, irrespective of its approval status. However, the use of drugs outside their approved indication(s) is associated with problems regarding their prescription at the expense of statutory health insurance funds. The latter is based on Article 2, Section 1, Subsection 3, Article 70; Section 1, Subsection 1; and Article 72, Section 2 of the German Social Code ( Sozialgesetzbuch, SGB ) Book V; and especially on Article 12, Section 1 SGB V (cost effi ciency). In keeping with the seminal ruling by the German Federal Social Court on March 19, 2002 (B 1 KR 37/00 R), off-label prescription at the expense of statutory health insurance funds is only possible in special cases. Whether such a special case exists has to be reviewed based on strictly defi ned criteria.
Thus, off-label prescription of a fi nished medicinal product is only acceptable, if -the disease to be treated is severe, life-threating or associated with lasting impairment of quality of life, -no other treatment is available, and -there is suffi cient evidence to reasonably believe that treatment success (curative or palliative) can be achieved with the respective drug.
Only prednisone and prednisolone are approved for systemic treatment of pyoderma gangrenosum.
Based on RCTs, cyclosporine and infliximab are good therapeutic options.
Given that many drugs are not approved for the treatment of leg ulcers, their use is off-label.
However, the use of drugs outside their approved indication(s) is associated with problems regarding their prescription at the expense of statutory health insurance funds.
In order to be able to assume the latter, there must be scientifi c evidence indicating that the drug can be approved for the respective indication. This can be expected, if -a request for approval expansion has already been submitted, and the results of a controlled clinical phase III trial (against standard or placebo) has been published, demonstrating clinically relevant effi cacy or clinically relevant benefi ts with acceptable risks, or -data obtained outside of the approval process has been published that provides reliable, scientifi cally verifi able evidence for the quality and effi cacy of the drug for the new indication, based on which there is consensus among experts as regards the expected benefi ts as defi ned above.
It is important to bear in mind that all three criteria must be met. Several of the disorders presented herein are rare diseases, also referred to as orphan diseases. In Europe, diseases that occur in fewer than 5 out of 10,000 inhabitants are considered orphan diseases. Given that there are frequently no approved drugs for the treatment of these disorders, off-label use is common.
Impact of systemic agents on wound healing
In recent years, there has been increasing scientifi c evidence that there are drugs that potentially promote wound healing in various indications. In animal studies, the calcium channel blockers nifedipine and amlodipine were associated with an increase in wound tensile strength compared to the control group. This effect was attributed to enhanced cross-linking (maturation) of collagen fi bers [ 51 ] .
Beta blockers are also used in the treatment of wounds, especially in burn patients. It has been shown that these agents mitigate the proinfl ammatory stress response, which is associated with muscle wasting and impaired wound healing [ 52 ] . What is more, beta blockers promote keratinocyte migration and thus accelerate re-epithelialization [ 53 ] .
Low-molecular-weight heparin affects wound healing by promoting fi broblast proliferation and collagen formation via increased expression of basic fi broblast growth factor (bFGF) and transforming growth factor beta 1 (TGF-β 1) [ 54 ] . A meta-analysis of the effect of heparin on wound healing in burn patients showed that heparin had a benefi cial impact on mortality as well as wound and graft healing [ 55 ] . A recent meta-analysis that included three studies with a total of 439 patients demonstrated that low-molecular-weight heparin was associated with signifi cant improvement in wound healing and lower recurrence rates in patients with chronic wounds of various origins [ 56 ] .
It has long been known that acetylsalicylic acid has a potentially benefi cial effect on wound healing. In part, this effect is attributable to the (irreversible) inhibition of cyclooxygenase enzymes, which are responsible for the synthesis of prostaglandins [ 57 ] . This results in anticoagulant, analgesic, and antiinfl ammatory effects. Newly discovered mechanisms of action include antiinfl ammatory effects by increased expression of lipoxins; these are signaling molecules that regulate various leukocyte functions. Thus, aspirin administration seems to have benefi cial effects on wound healing, in particular during the infl ammatory stages of various types of chronic wounds [ 58 ] .
Conclusion for practical use
Many of the therapeutic options presented herein are used off-label. Their use is frequently suggested by clinical experience and small studies. However, it must be In recent years, there has been increasing scientific evidence that there are drugs that potentially promote wound healing in various indications.
borne in mind that coverage by statutory health insurance funds is not guaranteed in most cases, given that, based on a ruling by the German Federal Social Court (BSG B1 KR 37/00 R), use of these drugs is only permitted in rare cases. While systemic drugs are promising options for the more common types of wounds such as venous and arterial leg ulcers, they do not represent the current standard of treatment. By contrast, systemic drugs play a key role in the management of many of the other -predominantly infl ammatory -disorders presented herein. Agents successfully used primarily include immunomodulatory and rheological drugs (Table 3 ) . Whether these and other drugs may promote wound healing in other indications, too, is the topic of current research. For many indications, however, there is still insuffi cient scientifi c evidence to make conclusive recommendations for everyday clinical practice. 
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